Blefarospasmo y espasmo hemifacial: tratamiento a largo plazo con toxina botulínica

Polo, C. Gil; Sanz, M.F. Rodríguez; Berrocal-Izquierdo, Nuria; Sanz, A. Castrillo; Ríos, R. Gutiérrez; Garcia, Melissa; Rodríguez, A.; García-Luis, Jacinto Duarte

doi:10.1016/j.nrl.2012.03.009

Cited by 14 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, our study partially agree with that published by Gil-Polo et al 22 who reported that repeated injections of BTA are efficacious and well tolerated in the long-term treatment of BPS. Although the follow-up and the sample of our study were greater, we observed fewer incidences Table 3.…”

Section: Discussionsupporting

confidence: 93%

“…of pretarsal injections (15.4%) than in the Gil-Polo study (41.2%). 22 Additionally, the results of our study are consistent with many of those previously published with shorter follow-up periods [22][23][24][25] regarding not only the efficacy of the BTA but also the epidemiological findings (age at onset and female predominance).…”

Section: Discussionsupporting

confidence: 91%

“…Nevertheless, the incidence of adverse events in our study is similar to that previously reported by other studies 16,24,27 and significantly lower than that published in the Gil-Polo et al's study. 22 As in prior studies 16,22,24,25,28 ptosis was the most common side effect (25%) following by haematoma (9%). Nevertheless, side effects were well tolerated in our series and were not related to treatment withdrawal.…”

Section: Discussionmentioning

confidence: 53%

See 2 more Smart Citations

Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm

Vivancos-Matellano

Rodríguez-Sanz

Herrero-Infante

et al. 2018

Neuro-Ophthalmology

View full text Add to dashboard Cite

Blepharospasm (BPS) is one of the most frequent types of facial dystonia and, at the same time, one of the most disabling, being able to trigger functional blindness if not treated. Our aim with this work was to evaluate the efficacy and safety of long-term onabotulinum A toxin (BAT) treatment in a cohort of patients with BPS. The retrospective study was conducted on consecutive patients with BPS treated with subcutaneous BAT. The selection of muscles and dose was made based on each patient's needs. The clinical and demographic characteristics, number of sessions, dose, duration and effectiveness of treatment, and adverse events were analysed. 130 patients were included in the study. The median (95% confidence interval) length of follow-up was 14 (13-15.6) years with an average of 20.5 sessions (range from 10 to 57). Regarding the efficacy of the treatment, 114 (87.7%) experienced satisfactory results with functional and aesthetics recovery. Patient evaluation of global response suggested a clear improvement without adverse events in 72 (55.4%) patients. Adverse events developed at least once during the treatment in 39% of patients, with transient ptosis and haematoma the most common reported both by physician and patient. The results of our study suggest that botulin toxin A is a safe and effective long-term treatment for blepharospasm with mild, transient and well-tolerated side effects when they appear.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 53%

See 1 more Smart Citation

Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm

Vivancos-Matellano

Rodríguez-Sanz

Herrero-Infante

et al. 2018

Neuro-Ophthalmology

View full text Add to dashboard Cite

show abstract

“…MVD is an effective and safe treatment option in HFS or trigeminal neuralgia [6,7], but there are still concerns regarding elderly patients. Most studies on the efficacy and safety of MVD in elderly patients were conducted with patients with trigeminal neuralgia [10,11,12,14,22].…”

Section: Discussionmentioning

confidence: 99%

“…Both are regarded as effective and safe for long-term management [6,7]. Among these treatment options, MVD is currently the only etiology-based therapy with an excellent outcome [8] and many studies also show an excellent surgical outcome in Korea [8,9].…”

Section: Introductionmentioning

confidence: 99%

Safety and Effectiveness of Microvascular Decompression for the Treatment of Hemifacial Spasm in the Elderly

Youn¹,

Kwon²,

Kim³

et al. 2013

Eur Neurol

View full text Add to dashboard Cite

Background: Hemifacial spasm (HFS) is a common disorder and has a significant impact on the quality of life. Microvascular decompression (MVD) is an effective and safe treatment option for patients with HFS, however the effectiveness and safety of MVD in elderly patients with HFS is not clear. Methods: We enrolled 699 HFS patients who underwent MVD from February 2008 to December 2011 at the Samsung Medical Center in Seoul, Korea. Subjects were divided into two groups: an elderly group (patients who were 60 years old or older) and a younger group. We compared demographic and clinical data, surgical outcome and complications after MVD between the groups. Results: The elderly group had more severe spasms and higher grade indentation than the younger group. Multiple offending vessels were more commonly detected in the elderly group. Although the improvement was similar 6 months after MVD between the groups, complications were more common in the elderly group even after controlling for possible confounding factors. In particular, ear problems including hearing loss were more common in the elderly group. Conclusion: MVD is an effective treatment option in elderly patients with HFS. However, surgeons should be pay attention to potential complications in elderly patients with HFS.

show abstract

Botulinum Neurotoxins as Therapeutics

Mehanna¹,

Jankovic²

2014

Handbook of Neurotoxicity

View full text Add to dashboard Cite

Blefarospasmo y espasmo hemifacial: tratamiento a largo plazo con toxina botulínica

Abstract: BS and HFS are the most common facial movement disorders. The demographic and clinical characteristics and therapeutic findings from this study show that treatment with BtA is both effective and safe over the long term.

Cited by 14 publications

References 15 publications

Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm

Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm

Safety and Effectiveness of Microvascular Decompression for the Treatment of Hemifacial Spasm in the Elderly

Botulinum Neurotoxins as Therapeutics

Contact Info

Product

Resources

About